Stimulation of Reactive Oxygen Species Production and Cytotoxicity in Human Neutrophilsin vitroand after Oral Administration of a Polyenzyme Preparation

Abstract

Polymorphonuclear neutrophils (PMN) can be primed for enhanced release of reactive oxygen species (ROS) by exposure to cytokines and biological response modifiers. ROS are considered to possess tumoricidal activity. The polyenzyme preparation Wobenzym (WE) contains pancreatin, papain, bromelain trypsin and chymotrypsin and is used in adjuvant tumor therapy. We investigated killing of WE-exposed PMN against tumor cells and analyzed WE influence on ROS production in a chemiluminescence assay in PMN in vitro and in vivo. Depending on dose WE stimulates the cytotoxic capacity of PMN in vitro against tumor cells (50 micrograms/ml:p < 0.01). Exposure of PMN to Wobenzym caused a time-dependent significant (p < 0.02) increase in release of ROS. Similarly, oral administration of Wobenzym to healthy volunteers (n = 28) resulted in significant increases (p < 0.01) in ROS production, depending on dose (peak with 20 tablets) and time (peak 4 hours after Wobenzym administration). In contrast, ROS production was not elevated in the PMN of healthy volunteers receiving placebo (n = 8) or no treatment (n = 16). These findings point to an immunomodulatory capacity of WE in adjuvant tumor therapy.

Recurrent Respiratory Infections in Children – Definition, Diagnostic Approach, Treatment and Prevention

“…The positive results achieved by the administration of SET can be explained by favourable immunomodulatory effects of these preparations (Honzikova et al, 2004). Similar effects were also observed other authors (Helms and Miller, 2006;Lanchava et al, 2005;Zavadova et al, 1995). Interesting finding was also the observed improvement in spirometric lung function indices following the application of SET in children with recurrent obstructive bronchitis (Lanchava et al, 2005).…”

“…Enzymes bind to the blood antiproteases after resorption through the mucosa of gastrointestinal tract and then they are distributed to sites of inflammation where they modulate and restore the imbalance in immune responses. They are involved in the activation as non-specific as specific immunity mechanisms (Biziulevicius, 1998;Desser et al, 2001;Douwe, 2005;Manhart et al, 2002;Targoni et al, 1999;Zavadova et al, 1995;Zavadova & Desser, 1997). Enzyme therapy can change the expression of adhesion molecules and receptors on the surface of T lymphocytes, reduce the activation of many populations of immunocompetent cells and they increase the activation threshold of autoaggressive T-lymphocytes in the mechanism of specific immunity (Biziulevicius, 1998;Desser et al, 2001;Douwe, 2005;Lauer et al, 2001;Manhart et al, 2002;Targoni et al, 1999;Zavadova et al, 1995;Zavadova & Desser, 1997).…”

Proteolytic Enzyme Therapy in Evidence-Based Complementary Oncology: Fact or Fiction?

“…17 Finally, proteolytic enzymes influence the levels of antioxidant enzymes and reactive oxygen species. 18 Recently, a novel role for extracellular proteases as inhibitors of intracellular signal transduction pathways has been described. 5 …”

Enzymes, Trophoblasts, and Cancer: The Afterlife of an Idea (1924-2008)

“…"These findings point to an immunomodulatory capacity of Wobenzym in adjuvant tumor therapy," she wrote. 50 1999. R. Kaul et al, of the SGPT Cancer Hospital, Indore, India, showed that Wobe-Mucos oral enzymes acted as potent anti-inflammatory and antiedematous agents, thereby decreasing acute toxic effects of radiation and increasing compliance and quality of life of cancer patients.…”